Anthem Blue Cross Wegovy Coverage: State-by-State Reality Check

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · As of May 2026, confirm directly with your plan

Key Takeaways

• Anthem is not a single insurer; it is 14 state Blue Cross plans under the Elevance Health corporate parent, each with state-specific formulary and contract rules
• Most Anthem fully insured commercial plans cover Wegovy with prior authorization, but self-funded employer plans frequently exclude it
• CarelonRx, Anthem's in-house PBM, took over pharmacy administration for most Anthem plans in 2024, changing prior authorization workflows
• The March 2024 FDA cardiovascular indication added a coverage pathway for members with established heart disease
• State Medicaid managed care plans administered by Anthem follow state Medicaid formulary rules, not Anthem's commercial formulary

Direct answer

Many Anthem commercial plans cover Wegovy with prior authorization as of May 2026, but coverage varies significantly across Anthem's 14-state footprint, individual employer contracts, and Medicaid managed care plans. Self-funded employer plans frequently exclude anti-obesity medications regardless of Anthem's administrative role. The 2024 cardiovascular indication created an additional pathway for members with established heart disease. Verify with your specific plan and CarelonRx formulary.

Table of contents

1. Anthem's 14-state footprint and Elevance Health structure
2. CarelonRx and the PBM transition
3. Fully insured vs self-funded: why this matters more than which insurer
4. Standard Anthem prior authorization for Wegovy
5. The cardiovascular indication pathway
6. Anthem Medicaid coverage state-by-state
7. Cost scenarios across Anthem plan types
8. Appealing an Anthem denial
9. The compounded semaglutide question for Anthem members
10. The contrary view: anti-obesity drug exclusions and employer economics
11. Decision framework
12. FAQ
13. Sources

Anthem's 14-state footprint and Elevance Health structure

Anthem, Inc. rebranded as Elevance Health in 2022. The corporate parent operates Anthem Blue Cross and Blue Shield plans in 14 states: California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin.

Each state plan operates under a separate Blue Cross Blue Shield Association license with state-specific regulatory requirements. State insurance departments approve formularies, mandate certain coverage benefits, and enforce mental health parity rules. This produces meaningful variation across the 14 states.

California, for example, has additional state mandates around utilization management that affect prior authorization timelines. New York operates under a state-specific external review process for denials. Virginia has different parity enforcement standards than Indiana. These structural differences shape how a Wegovy prior authorization will be processed.

The Elevance Health corporate structure also includes Wellpoint Medicaid plans in additional states, Carelon health services (which includes CarelonRx PBM), and various specialty pharmacy operations. The corporate sprawl means a "Wegovy denial from Anthem" can come from many different underwriting and clinical review pathways.

CarelonRx and the PBM transition

Anthem's relationship with pharmacy benefit management has shifted multiple times over the past decade. Before 2017, Express Scripts administered Anthem's PBM. From 2017 through 2023, IngenioRx (Anthem's joint venture with CVS) handled pharmacy benefits. Beginning in 2024, CarelonRx (the renamed and restructured in-house PBM under Elevance Health) took over most Anthem pharmacy benefit administration.

For Wegovy coverage, the transition affects:

• Prior authorization submission portals (now CarelonRx, not IngenioRx)
• Formulary tiering decisions
• Specialty pharmacy fulfillment routing
• Appeals processes for pharmacy denials

Members who had Wegovy approved under the prior PBM should not assume coverage transfers automatically. Several Anthem members reported PA reauthorization requirements when CarelonRx assumed administration. Pharmacy benefit transitions are an underappreciated source of coverage interruption.

Fully insured vs self-funded: why this matters more than which insurer

Anthem administers two structurally different plan types. The distinction matters more than the Anthem brand on the card.

Fully insured plans: Anthem (or the state Anthem entity) collects premiums and assumes the financial risk for member care. State insurance department regulation applies. Coverage decisions follow Anthem's standard formulary unless the employer purchased a customized rider.

Self-funded plans: The employer pays for member claims directly. Anthem only administers the plan. Federal ERISA preemption applies, not state insurance law. The employer designs the benefit, including whether anti-obesity medications are covered. Anthem cannot override employer-designed exclusions.

Roughly 65% of employer-covered Americans are in self-funded plans, per the Kaiser Family Foundation Employer Health Benefits Survey. For Wegovy specifically, the rate of self-funded plan exclusion of anti-obesity drugs is higher than fully insured plan exclusion because employers are more cost-sensitive when they bear direct financial risk.

Members with Anthem cards should check their Summary Plan Description (SPD) for an anti-obesity medication exclusion. If the SPD excludes the category, no prior authorization will overcome that exclusion. If the SPD does not exclude, normal Anthem PA rules apply.

Standard Anthem prior authorization for Wegovy

CarelonRx prior authorization for Wegovy generally requires:

1. BMI 30 or higher, or BMI 27 with documented comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
2. Documentation of participation in a structured weight-management program for typically 6 months
3. Demonstration of medical necessity by the prescribing clinician
4. Sometimes, prior trial of formulary alternatives such as phentermine or contrave
5. Attestation that contraindications are absent (personal or family history of medullary thyroid carcinoma or MEN 2 syndrome)

Initial approval is typically 6 months, with continuation requiring documentation of clinically meaningful weight loss (usually 5% or more) at reauthorization. Members who fail to demonstrate adequate response may face non-renewal.

Some Anthem state plans have additional requirements. New York requires demonstrated failure of at least one other anti-obesity medication. California requires documented BMI history showing chronicity. Virginia and Indiana have lower documentation thresholds.

The cardiovascular indication pathway

The March 2024 FDA approval of Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity opened a parallel coverage pathway. The approval was based on the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), which enrolled 17,604 patients and demonstrated a 20% relative reduction in major adverse cardiovascular events.

Anthem coverage policies for the CV indication typically require:

• Established atherosclerotic cardiovascular disease (prior MI, prior stroke, or angiographically confirmed coronary artery disease)
• BMI 27 or higher
• Cardiology consultation or co-signature
• Sometimes, documentation of statin therapy and other cardiovascular medications

The CV indication is reimbursable as cardiovascular care, not obesity treatment. Anthem plans that exclude anti-obesity drugs but cover cardiovascular medications can still cover Wegovy under this indication. Members with established heart disease should explicitly pursue this pathway rather than the standard obesity PA.

Anthem Medicaid coverage state-by-state

Anthem administers Medicaid managed care in several states. Medicaid Wegovy coverage is determined by state Medicaid programs, not by Anthem's commercial formulary.

State Medicaid	Wegovy coverage status (as of May 2026)
California Medi-Cal	Partial coverage; PA required, BMI 35+ typical threshold
Indiana Medicaid	Coverage added 2024; PA required
Ohio Medicaid	Restricted; coverage limited to specific PA criteria
Kentucky Medicaid	Coverage with PA; structured weight management requirement
Virginia Medicaid	Variable by managed care organization
Georgia Medicaid	Limited; mostly excluded
New York Medicaid	Coverage available; PA required

State Medicaid coverage is a moving target. The Inflation Reduction Act and ongoing CMS guidance about anti-obesity medications continues to reshape state coverage decisions. Members should check their specific state Medicaid drug list rather than rely on Anthem's commercial formulary.

Cost scenarios across Anthem plan types

Plan type	Approximate monthly Wegovy cost
Fully insured, tier 2	$25 to $50
Fully insured, tier 3	$50 to $100
Specialty tier	$100 to $300
Self-funded with coverage	Variable; employer-set
Self-funded with exclusion	$1,350 retail, $499 NovoCare
Medicaid covered	$0 to nominal copay
NovoCare direct-pay	Approximately $499

Appealing an Anthem denial

Anthem denial appeals follow a standard pathway:

1. Initial denial from CarelonRx, with documented basis (failure to meet PA criteria, lack of medical necessity, formulary exclusion)
2. First-level internal appeal: 30 days from denial typically, requires additional clinical documentation
3. Peer-to-peer review: optional but useful, allows your prescriber to speak directly with an Anthem medical director
4. Second-level internal appeal
5. External review through state Independent Review Organization

Appeal strategy notes:

• Submit complete clinical documentation, not just narrative letters
• For obesity indication: emphasize BMI history, comorbidities, and prior intervention attempts
• For CV indication: include the SELECT trial citation and explicit cardiology documentation
• Track all deadlines; missed deadlines forfeit appeal rights
• Self-funded ERISA plans have different appeal mechanics; the Department of Labor handles ERISA appeals, not state insurance departments

The compounded semaglutide question for Anthem members

During the semaglutide shortage (2022 through October 2024), many Anthem members turned to compounded semaglutide from telehealth providers when Anthem coverage was denied or when CarelonRx exception processes were too slow. The FDA's October 2024 declaration that semaglutide was no longer in shortage triggered enforcement action against many compounders.

As of May 2026, compounded semaglutide remains available through some 503A pharmacies operating under personalization exceptions. Anthem does not cover compounded semaglutide; the product is not FDA-approved and is not the same as Wegovy.

For Anthem members weighing options:

• Pursue Anthem coverage first; the CV indication is the most accessible new pathway
• If denied, file appeals and explore NovoCare direct-pay as a bridge
• Compounded semaglutide is a different product with different regulatory status; understand the differences before deciding
• FormBlends does not sell brand-name Wegovy and is not affiliated with Anthem or Novo Nordisk

The contrary view: anti-obesity drug exclusions and employer economics

The standard frame is that self-funded employers excluding anti-obesity medications are being short-sighted, sacrificing long-term health to save short-term dollars. The frame has merit, but the underlying economics deserve a steelman.

A self-funded employer covering Wegovy for eligible members at typical pricing assumes a multi-million-dollar annual cost increase for mid-sized employers. The cost-effectiveness analyses produced by ICER and similar groups have repeatedly shown that anti-obesity medications at current pricing exceed standard quality-adjusted life-year thresholds. The downstream savings (reduced cardiovascular events, reduced diabetes incidence, reduced bariatric surgery) materialize over years to decades.

For an employer with high turnover, the economic case is even weaker. The employer covering Wegovy today may not retain the member long enough to capture the downstream savings. Employers do not internalize public health benefits.

This isn't a defense of exclusions, but it explains why they persist even among employers who genuinely care about employee wellbeing. The pricing structure of anti-obesity medications is the underlying problem; employer exclusions are downstream of that.

Decision framework

If you have an Anthem fully insured commercial plan with BMI 30+: Pursue standard CarelonRx prior authorization. Document comorbidities. Complete required weight-management program participation. Expect approval if criteria met.

If you have an Anthem self-funded employer plan: Read your Summary Plan Description first. If anti-obesity drugs are excluded, prior authorization won't help; pursue alternative pathways or NovoCare. If not excluded, standard PA applies.

If you have established heart disease: Pursue the cardiovascular indication. This pathway has expanded substantially in 2024-2025 and offers coverage even in plans that exclude obesity drugs.

If you have Anthem Medicaid: Check your state Medicaid drug list. Coverage varies dramatically by state.

If you have been denied: File internal appeals. Request peer-to-peer review. Pursue external review through state IRO. For ERISA self-funded plans, file with Department of Labor.

FAQ

Does Anthem Blue Cross cover Wegovy? Sometimes, varies by state, plan type, employer contract, and indication.

Which states does Anthem cover? CA, CO, CT, GA, IN, KY, ME, MO, NV, NH, NY, OH, VA, WI.

What is CarelonRx? Elevance Health's in-house PBM that administers most Anthem pharmacy benefits as of 2024.

What is Anthem's prior authorization for Wegovy? BMI 30+ or BMI 27+ with comorbidities, structured weight-management documentation, medical necessity attestation.

How much does Wegovy cost with Anthem? Covered: $25 to $300. Uncovered: $1,350 retail or $499 NovoCare.

Does Anthem Medicaid cover Wegovy? Determined by state Medicaid program, not Anthem. Varies dramatically.

Can I appeal an Anthem Wegovy denial? Yes, internal and external appeal processes exist.

Does Anthem cover Wegovy for heart disease? Coverage for the CV indication has expanded since March 2024.

What if my employer plan excludes Wegovy? ERISA self-funded exclusions cannot be overridden by Anthem. Pursue alternative pathways.

Sources

1. FDA, Wegovy (semaglutide) prescribing information, cardiovascular risk reduction indication, March 2024
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. November 2023
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021
4. CarelonRx Formulary Guide, 2026 plan year, Anthem state editions
5. Elevance Health corporate filings, 2024 PBM transition disclosures
6. Kaiser Family Foundation, Employer Health Benefits Survey, 2024 edition
7. Centers for Medicare and Medicaid Services, Medicaid drug coverage guidance, 2024-2025
8. State Medicaid drug lists: California, Indiana, Ohio, Kentucky, Virginia, Georgia, New York, accessed May 2026
9. Novo Nordisk, NovoCare direct-pay program materials, 2025-2026
10. ERISA appeals procedures, US Department of Labor, EBSA guidance
11. Institute for Clinical and Economic Review, Anti-Obesity Medications, Evidence Report, 2022
12. Endocrine Society, Pharmacological Management of Obesity, Clinical Practice Guideline, 2022 update

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacies. We have no commercial relationship with Anthem, Elevance Health, CarelonRx, or Novo Nordisk. Coverage information reflects publicly available data as of May 2026 and is subject to ongoing change.

Compounded Medication Notice. Compounded semaglutide is a 503A pharmacy preparation, not FDA-approved, and not therapeutically equivalent to brand Wegovy. Patient-specific compounded preparations are exempt from pre-market approval but remain subject to state pharmacy board oversight and USP standards.

Results Disclaimer. Trial-reported weight, cardiovascular, and metabolic outcomes reflect average effects in study populations. Real-world results vary by adherence, baseline metabolic status, dose tolerability, and lifestyle factors. Individual outcomes are not guaranteed.

Trademark Notice. Wegovy and Saxenda are registered trademarks of Novo Nordisk A/S. Anthem and Anthem Blue Cross are registered marks of Elevance Health, Inc. CarelonRx is a registered service mark of Elevance Health. Blue Cross Blue Shield is a registered mark of the Blue Cross Blue Shield Association. References are informational.